Ipamorelin + CJC-1295 Research
Growth Hormone Secretagogue Combination
Research area: growth hormone signaling
This combination pairs Ipamorelin, a selective GHRP (growth hormone releasing peptide), with CJC-1295, a GHRH (growth hormone releasing hormone) analog. Research studies how pairing a pituitary GHSR agonist with a hypothalamic GHRH analog affects growth hormone axis signaling.
Research Areas
Dual-Axis GH Secretagogue Signaling
Studies examine how Ipamorelin acts on GHSR (growth hormone secretagogue receptor) while CJC-1295 binds GHRH receptors, and research investigates whether this combination produces additive effects on GH pulse amplitude via two separate signaling pathways.
IGF-1 Axis Research
Research explores how sustained GH elevation through combined GHRH/GHRP signaling may affect downstream IGF-1 signaling pathways and their relationship to cellular anabolism pathway research.
Body Composition Signaling
Phase 1/2 clinical studies with CJC-1295 investigated changes in lean tissue and fat mass markers. Research continues on the combined signaling effects on metabolic and body composition pathways.
Nocturnal GH Release Patterns
Research investigates the relationship between GH secretagogue signaling and nocturnal growth hormone pulse research, which naturally peaks during slow-wave sleep phases.
Growth hormone axis research; both are investigational compounds.
Research References
Discuss any health concerns with a licensed clinician before making health decisions.
Have questions about Ipamorelin + CJC-1295?
Request a free consultation to ask questions and learn more about this research area.
Affiliate disclosure: I am an independent affiliate of The Longevity Consultants and may receive compensation if you request a consultation through me.
Request a free consultation